Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Regeneus Ltd. ( (AU:CMB) ) just unveiled an announcement.
Cambium Bio Limited has successfully raised A$2.12 million through a fully-subscribed placement of new shares, with significant investment from Da Jyun Capital Investment Corporation, a Taiwanese firm experienced in regenerative medicine. This funding will support the initiation of Phase 3 trials for Elate Ocular and enhance Cambium Bio’s strategic positioning in the market, potentially leading to global licensing discussions with major pharmaceutical companies.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company focused on ophthalmology and tissue repair.
Average Trading Volume: 10,479
Technical Sentiment Signal: Sell
Current Market Cap: A$5.85M
For a thorough assessment of CMB stock, go to TipRanks’ Stock Analysis page.